Lacrimal Duct Stent Tube Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Lacrimal Duct Stent Tube Market is Segmented by Product Type (Monocanalicular Lacrimal Duct Stent Tube and Bicanalicular Lacrimal Duct Stent Tube), End User (Hospitals, Ophthalmic Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Lacrimal Duct Stent Tube Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Lacrimal Duct Stent Tube Market Size

Lacrimal Duct Stent Tube Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 5.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Lacrimal Duct Stent Tube Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Lacrimal Duct Stent Tube Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Lacrimal Duct Stent Tube Market Analysis

The Lacrimal Duct Stent Tube Market is expected to register a CAGR of 5.2% during the forecast period.

The COVID-19 pandemic presented significant hurdles for the healthcare sector. Since the majority of surgical procedures were considered to be non-urgent, all outpatient consultations were delayed or restricted during the COVID-19 pandemic to lower the danger of viral transmission. Thus, the lacrimal duct stent market was adversely impacted during the pandemic. However, it is expected to gain traction in the post-pandemic era due to the resumption of surgical procedures.

Certain factors that are driving the market include the increasing patient pool for nasolacrimal duct obstruction and rising demand for treatments with minimal invasions and better success rates. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common disorder of the lacrimal system. According to the August 2022 updated report, published by the NCBI, congenital nasolacrimal duct obstruction may occur in 3-6% of newborns, while it occurs bilaterally in 20% of newborns. There is a high rate of spontaneous resolution of congenital nasolacrimal duct obstruction, with approximately 70% of affected children being free of the symptoms by 3 months of age, and over 90% recovering by their first birthday. However, infants at increased risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital, and ear anomalies) syndrome, and Goldenhar syndrome. Hence, the rising prevalence of such health conditions is expected to drive the market over the forecast period.

New studies on lacrimal stent tubes help expand the applications for various conditions, which is expected to boost the market's growth over the forecast period. For instance, as per the study published by the European Journal of Ophthalmology in December 2021, lacrijet monocanalicular stent intubation has a high rate of success, shortens the surgical time, and has a low rate of complications in children with congenital nasolacrimal duct obstruction. Hence, the new studies on lacrimal stent tubes expand the indications and provide the safety and efficacy of the stents, which may drive the market over the forecast period.

However, complications associated with stent tubes are likely to hinder the growth of the market over the forecast period.

Lacrimal Duct Stent Tube Industry Overview

The lacrimal duct stent tube market is consolidated and consists of very few major players. Companies like Aurolab, Bess Medizintechnik GmbH, ZEISS (FCI Ophthalmics), Gunther Weiss Scientific Glassblowing Co. Inc., and Kaneka Pharma America LLC hold a substantial market share.

Lacrimal Duct Stent Tube Market Leaders

  1. ZEISS (FCI Ophthalmics)

  2. Aurolab

  3. bess medizintechnik gmbh

  4. Kaneka Medical America LLC

  5. Gunther Weiss Scientific Glassblowing Co., Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Lacrimal Duct Stent Tube Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Lacrimal Duct Stent Tube Market News

  • In May 2022, AffaMed Therapeutics held a DEXTENZA launch and Advisory Board Meeting in Macau. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.
  • In February 2021, FCI Ophthalmics launched the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single-use injector, according to FCI Ophthalmics.

Lacrimal Duct Stent Tube Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Patient Pool for Nasolacrimal Duct Obstruction
    • 4.2.2 Rising Demand for Treatments with Minimal Invasions and Better Success Rates
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Stent Tubes
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Monocanalicular Lacrimal Duct Stent Tube
    • 5.1.2 Bicanalicular Lacrimal Duct Stent Tube
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ophthalmic Clinics
    • 5.2.3 Other End Users
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aurolab
    • 6.1.2 Bess Medizintechnik GmbH
    • 6.1.3 ZEISS (FCI Ophthalmics)
    • 6.1.4 Gunther Weiss Scientific Glassblowing Co. Inc.
    • 6.1.5 Kaneka Medical America LLC
    • 6.1.6 BD (Becton, Dickinson and Company)
    • 6.1.7 BVI Medical Inc.
    • 6.1.8 Walsh Medical Devices Inc.
    • 6.1.9 Surtex Instruments Limited
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Lacrimal Duct Stent Tube Industry Segmentation

As per the scope of the report, a lacrimal stent is a hollow silicone tubing with a non-traumatic tip. The tubing is securely attached to malleable stainless steel probes that are used to guide the silicone tubing through the lacrimal drainage apparatus. Lacrimal stents are used to reduce the risk of recurrent stenosis of the nasolacrimal duct. 

The lacrimal duct stent tube market is segmented by product type (monocanalicular lacrimal duct stent tube and bicanalicular lacrimal duct stent tube), end user (hospitals, ophthalmic clinics, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product Type Monocanalicular Lacrimal Duct Stent Tube
Bicanalicular Lacrimal Duct Stent Tube
By End User Hospitals
Ophthalmic Clinics
Other End Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Lacrimal Duct Stent Tube Market Research FAQs

What is the current Lacrimal Duct Stent Tube Market size?

The Lacrimal Duct Stent Tube Market is projected to register a CAGR of 5.2% during the forecast period (2025-2030)

Who are the key players in Lacrimal Duct Stent Tube Market?

ZEISS (FCI Ophthalmics), Aurolab, bess medizintechnik gmbh, Kaneka Medical America LLC and Gunther Weiss Scientific Glassblowing Co., Inc. are the major companies operating in the Lacrimal Duct Stent Tube Market.

Which is the fastest growing region in Lacrimal Duct Stent Tube Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Lacrimal Duct Stent Tube Market?

In 2025, the North America accounts for the largest market share in Lacrimal Duct Stent Tube Market.

What years does this Lacrimal Duct Stent Tube Market cover?

The report covers the Lacrimal Duct Stent Tube Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Lacrimal Duct Stent Tube Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Lacrimal Duct Stent Tube Industry Report

Statistics for the 2025 Lacrimal Duct Stent Tube market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Lacrimal Duct Stent Tube analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.